People
The People Running This Company
Governance grade: B+. A career-insurance CEO running a fortress board (10 of 11 directors independent, separate independent chair, every committee chair independent), no disclosed related-party transactions, and clean Form 4 activity — but pay keeps rising even as 2025 net income fell ~25%, the CEO-to-median-worker ratio is 278:1, and the largest shareholder block (16.2%, the policyholder trust) votes as the Board directs.
1. The People Running This Company
MetLife is run by long-tenured insurance operators, not founders or owners. Khalaf came up through the legacy Alico/EMEA business and has been at MetLife since 2011; the rest of the named-officer team has been promoted internally. The story is professionalized continuity, not founder energy.
CEO 2025 Total Comp
CEO Direct Stock Value ($M)
CEO : Median Worker
CEO Ownership Guideline (× base)
Why this matters: Khalaf and the four other NEOs were promoted into their roles, not parachuted in. There is institutional memory, but no founder lock-in. Succession exists on paper (CEO succession is reviewed annually by the Governance Committee) but no obvious internal heir is publicly identified.
2. What They Get Paid
CEO target pay is heavily equity-weighted (~66% performance shares + RSUs in 2025), but realized pay shows the soft spot: total comp rose 10% in 2025 even though net income to common fell from $4.23B to $3.17B and ROE dropped from 16.9% to 12.9%. The Compensation Committee leaned on multi-year operating metrics (Adjusted Earnings, ROE, free cash flow) rather than the GAAP miss, which is defensible — but the optics are weak.
Pay-for-performance tension: Every NEO got a raise in a year when GAAP net income fell ~25% and ROE compressed by 4 points. The bonus pool was flat (cash incentive unchanged at $4.6M for the CEO since 2024), so the increase came almost entirely from the equity grant — which was sized off three-year operating performance, not 2025 results. Defensible, but worth watching if 2026 results disappoint again.
3. Are They Aligned?
This is the strongest part of the case. The signal here is overwhelmingly clean, with one structural quirk worth flagging.
The PH Trust is a leftover from the 2000 demutualization: shares belong to former mutual policyholders, but on most ballot items the trustee votes per the Board's recommendation. That gives the board ~16% of the vote on contested matters — a rare structural feature for a US-listed insurer that effectively neutralizes activist pressure.
No discretionary insider selling. Across 72 Form 4 filings in the past seven months, there are zero open-market sells and zero open-market buys. Every disposition is a code-F sell-to-cover for tax withholding on RSU vesting. Every acquisition is a grant or DRIP. Insiders are letting their stakes accumulate.
Skin-in-the-Game Score (1–10)
Skin-in-the-game = 8/10. The CEO holds ~720K shares directly worth ~$53M at the recent ~$71 price — about 35× his $1.5M base. McCallion (~$20M), Tadros (~$15M), Pappas (~$6M), and Debel (~$11M) all clear their 4× guidelines comfortably. Buybacks have been MetLife's primary capital-allocation lever (~$5–6B/year), the dividend was raised 4.4% in early 2026, and there are no reported promoter pledges, hedging, or related-party transactions. Score is held to 8 (not 10) because none of these executives founded the firm or has a stake big enough to make them a meaningful economic owner of MetLife's $52B market cap — they are well-paid stewards, not co-owners.
Related-party transactions: "To the Company's knowledge, since January 1, 2025, there are no Related Person Transactions requiring disclosure under Item 404 of Regulation S-K." Clean.
4. Board Quality
Board is unusually deep on what actually matters for a global multi-line insurer: a CEO of a peer reinsurer (Mumenthaler, ex-Swiss Re), a CEO of the world's largest insurance broker (Glaser, ex-Marsh & McLennan), the former Global Head of Insurance at KPMG (Hay), the former Global CEO of EY (Weinberger as Audit Chair), a serious public-policy economist (Hubbard), and a former DHS Secretary (Johnson) for cyber/regulatory.
Tenure mix is healthy. Five directors joined in 2022 or later (Harris '22, Johnson '23, Hay '24, Mumenthaler '25, Glaser & Seitz '26); only Hubbard (since 2007) is genuinely long-tenured, and his board-economist role makes that defensible. Average non-executive tenure is roughly seven years — long enough to know the company, short enough to avoid ossification.
Real weakness: no large independent shareholder voice. Unlike companies with founder-PE-pension representation, every director here is an outside professional. The board is high-quality and credentialed but has no skin-in-the-game director with a personally meaningful equity position; aggregate director ownership is below 0.05% of shares outstanding.
Watch item: The Khalaf-aligned CEO Executive Committee chair role is the only seat where independence is compromised. With 10/11 independent directors and a separate independent non-executive chair, this is a cosmetic concern, not a structural one.
5. The Verdict
Governance grade: B+.
Strongest positives
- 10 of 11 directors independent; separate independent non-executive chair; every committee chair independent.
- Zero discretionary insider selling across 72 recent Form 4s — every disposition is tax withholding on vesting.
- All NEOs above their 4–7× base-salary ownership guidelines; CEO holds ~$53M of stock directly.
- No related-party transactions disclosed since January 2025.
- Board expertise stacks the bench on insurance, audit, risk, government, and tech — exactly the right skills for this business.
Real concerns
- 2025 pay rose ~10% while GAAP net income fell ~25%; CEO-to-median pay ratio is 278:1.
- The PH Trust (16.2%) votes as the Board directs on most ballot items — a built-in defense against shareholder activism that cuts both ways.
- 2016 FINRA $25M annuity-switching settlement and 2024 OFAC $178K Iran-sanctions settlement are old, but they are the only two material conduct events on the public record and both predate this CEO's full pay-for-performance era ending well.
- TheLayoff.com chatter, sub-3% raise complaints, and ongoing GTO/HR/USB workforce cuts run alongside record buybacks — a labor-versus-capital allocation tension that has not yet shown up in attrition or sentiment data, but is worth tracking.
- No director has a personally meaningful equity stake (largest individual holder among directors: Hubbard at ~105K shares, ~$7M) — the board challenges management with credentials, not ownership.
One thing that would change the grade
- Upgrade to A−: another year of zero open-market insider selling plus a CEO pay reset that aligns 2026 grant levels with the 2025 earnings drop.
- Downgrade to B−: any new regulatory action implicating sales practices, a related-party transaction surfacing, or pay rising again in a second consecutive earnings-down year.